CSBio CSBio

X
[{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Biophytis"},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis to Present Full Results From the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 \u2013 October 2, 2021","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Biophytis"},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Has Filed with the EMA for Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Biophytis"},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Seeks US FDA Approval to Initiate SARA-31 Phase 3 Study in Sarcopenia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Biophytis"},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Obtains FDA Authorization to Initiate the SARA-31 Phase 3 Study in Sarcopenia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Biophytis"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Sarconeos (BIO101) activates the MAS receptor, a key component of the protective arm of the RAS, and has been shown to significantly improve respiratory function in several preclinical models. It is being developed for treating sarcopenia.

            Lead Product(s): 20-Hydroxyecdysone

            Therapeutic Area: Musculoskeletal Product Name: Sarconeos

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 11, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Sarconeos (20-hydroxyecdysone) activates the MAS receptor, a key component of the protective arm of the RAS, and has been shown to significantly improve respiratory function in several preclinical models. It is being developed for treating sarcopenia.

            Lead Product(s): 20-Hydroxyecdysone

            Therapeutic Area: Musculoskeletal Product Name: Sarconeos

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 10, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Sarconeos (BIO101) activates the MAS receptor, a key component of the protective arm of the RAS, involved in the regulation of smooth, cardiac and skeletal muscle metabolism and plays a key role in muscle function and mobility. It is being developed for sarcopenia.

            Lead Product(s): 20-Hydroxyecdysone

            Therapeutic Area: Musculoskeletal Product Name: BIO101

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 15, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Sarconeos (BIO101) showed a very good safety profile at the doses of 175 mg bid and of 350 mg bid. Based on the SARA-INT results, Biophytis is now preparing the phase 3 program and associated regulatory agency interactions.

            Lead Product(s): 20-Hydroxyecdysone

            Therapeutic Area: Musculoskeletal Product Name: BIO101

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 29, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The objective of the SARA-INT Phase 2 study is to evaluate the efficacy and safety of Sarconeos (BIO101) in a randomized placebo-controlled study in patients over 65 years suffering from sarcopenia and considered at high risk of mobility disability.

            Lead Product(s): 20-Hydroxyecdysone

            Therapeutic Area: Musculoskeletal Product Name: BIO101

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 30, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY